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Abstract
Background: Elderly nursing home residents are at increased risk of hip fracture; however, the efficacy of fracture
prevention strategies in this population is unclear.
Objective: We performed a scoping review of randomized controlled trials of interventions tested in the long-term care
(LTC) setting, examining hip fracture outcomes.
Methods: We searched for citations in 6 respective electronic searches, supplemented by hand searches. Two reviewers
independently reviewed all citations and full-text papers; consensus was achieved on final inclusion. Data was abstracted in
duplicate.
Findings: We reviewed 22,349 abstracts or citations and 949 full-text papers. Data from 20 trials were included: 7 - vitamin D
(n=12,875 participants), 2 - sunlight exposure (n=522), 1 - alendronate (n=327), 1 - fluoride (n=460), 4 – exercise or
multimodal interventions (n=8,165), and 5 - hip protectors (n=2,594). Vitamin D, particularly vitamin D3 $800 IU orally
daily, reduced hip fracture risk. Hip protectors reduced hip fractures in included studies, although a recent large study not
meeting inclusion criteria was negative. Fluoride and sunlight exposure did not significantly reduce hip fractures. Falls were
reduced in three studies of exercise or multimodal interventions, with one study suggesting reduced hip fractures in a
secondary analysis. A staff education and risk assessment strategy did not significantly reduce falls or hip fractures. In a
study underpowered for fracture outcomes, alendronate did not significantly reduce hip fractures in LTC.
Conclusions: The intervention with the strongest evidence for reduction of hip fractures in LTC is Vitamin D
supplementation; more research on other interventions is needed.
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Hip fractures are not uncommon in the nursing home setting,
with an estimated annual incidence rate of about 4% (range 2%–
6%) [1–15]. This risk is two to eleven times that of community-
dwelling elderly [5–9]. Within a year after sustaining a hip
fracture, an elderly nursing home resident has a 40% risk of death
[16] and a 6–12% risk of another hip fracture [16;17]. Most long-
term care (LTC) facility residents surviving a hip fracture never
regain pre-fracture functional status [18], and about two-thirds are
left without independent mobility [19;20]. The estimated one-year
healthcare cost of a hip fracture sustained in a LTC facility is
about $33,000 (Canadian) [21]. Thus, hip fractures sustained in
LTC facilities are an important source of mortality, morbidity, and
healthcare expenditures. Interventions that may be effective in
reducing the risk of hip fracture in community-dwelling elderly
may not necessarily be effective in the LTC setting because of
barriers such as resident comorbidities and concomitant prescrib-
ing contra-indications for osteoporosis drugs, frailty limiting
exercise tolerance, or staff compliance with proper administration
procedures (for drugs or devices).
Our objective was to conduct a scoping review (series of
systematic reviews), to identify interventions proven in randomized
controlled trials to reduce the risk of hip fracture in elderly nursing
home residents. The summary of evidence in this review is
intended to serve as a comprehensive resource for physicians,
administrators, and health policy makers with an interest in LTC
of the elderly. This review also highlights gaps in current
knowledge and the need for more research in this area.
Methods
Inclusion Criteria for Studies
We included published randomized controlled trials or
systematic reviews of randomized controlled trials of interventions
intended to reduce the risk of hip fracture in the nursing home
setting, as compared to placebo, sham intervention, usual care, or
an alternative intervention. More than half of the study population
was required to be comprised of elderly nursing home residents (or
equivalent, defined as individuals of a median or mean age of $65
years of age, residing in an institution with nursing care available
on-site 24 hours per day). Information on hip fracture outcomes
was a requirement for inclusion (reported either in the primary
publication or obtained from the author through correspondence).
A follow-up period (mean or median) of at least 6 months was
required. In the case of duplicate publications, only the largest
published trial with longest follow-up period was included. For the
systematic review of hip protectors, the inclusion criteria were the
same as those described in recent systematic reviews by our group
[22;23] as our most recent review [22] was updated herein. Ethical
approval was not required for this study.
Search Strategies
A review protocol was developed by experts in epidemiology/
knowledge synthesis, biostatistics, health economics, endocrinolo-
gy, geriatrics, and rheumatology (AS, LT, AG, AP, JA) (protocol
available from the corresponding author upon request). There
were 6 categories of interventions searched, including: a) vitamin
D or calcium (or vitamin D analogues), b) non-hormonal
pharmacologic therapies for osteoporosis, c) hormonal therapies
(or hormone analogues), d) oral or parenteral alternative
medicines, e) exercise, behavioral interventions, physiotherapy,
education, or multimodal interventions (including fall prevention
strategies), and f) hip protectors. Electronic search strategies were
directed by a librarian experienced in systematic reviews. There
were no language restrictions. Additional articles were identified
through reference lists or discussions with experts. The details of
the databases searched are listed in the Appendix S1.
Selection of Studies for Inclusion
Two reviewers independently scanned all abstracts and citations
and decided on relevance to the review. Any abstracts or citations
deemed potentially relevant by either reviewer were reviewed in
full-text form by two independent reviewers. Full-text papers were
included in this review only if consensus was achieved between
reviewers.
Validity Assessment
Two reviewers independently assessed methodologic quality of
included studies. Reviewers were not masked to the study authors
nor journals of publication. Key features in methodologic quality
assessment included a description of the level of randomization
(individual or cluster), the method of randomization, the utilization
of placebo or sham interventions, losses to follow-up, compliance
rates, and reporting of adverse events. In addition, for cluster
randomized trials, we examined whether the intra-cluster
correlation coefficient (or variance inflation factor attributed to
clustering) was reported and if the analysis was adjusted for cluster
randomization. The results of the validity assessment are
summarized in the Results under Study Characteristics.
Data Abstraction
All data were abstracted independently by two reviewers. A data
abstraction form including study characteristics and fracture
outcomes was utilized (sample data abstraction form available
from the corresponding author upon request). All data were
reviewed by AMS and any discrepancies were resolved among
reviewers. For the intervention of exercise or behavioural, or
multi-modal interventions, a supplemental data abstraction form
was provided to summarize falls outcomes as these were deemed
relevant for this particular set of interventions.
Statistical Analyses
Separate statistical analyses were planned for each of the 6
respective categories of interventions. A previously described
Bayesian random effects meta-analysis for pooling of intention-to-
treat data from individually or cluster randomized trials in the
nursing home setting [22] was used (Winbugs 1.4.1, MRC
Biostatistics Unit, Cambridge, UK) (random seed number
314159). We used non-informative priors in Bayesian models, as
previously published [22]. For the oral vitamin D meta-analyses,
we performed 10,000 simulations, with Gibbs sampling of results
for posterior distributions started at 1,000 (sampling every fifth
value); three chains were run simultaneously. For the hip protector
meta-analysis, we performed 10,000 simulations, with Gibbs
sampling of results for posterior distributions started at 1,000
(sampling every fifth value); three chains were run simultaneously.
For pooled cluster-randomized trials, an intra-cluster correlation
coefficient (ICC) of 0.0247 was imputed, if not reported [22]. This
ICC was derived from a comprehensive sensitivity analysis as
published previously [22]. We calculated the pooled odds ratio
(OR) of hip fracture in the treatment group relative to the control
group, with 95% credibility interval (CRI) [22]. A priori planned
subgroup analyses for oral vitamin D included separate analyses
for any form of vitamin D, vitamin D2, vitamin D3, and vitamin
D3 $800 IU daily (or equivalent), all based on findings of a prior
review [24]. If a Bayesian meta-analysis could not be performed,
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classical random effects meta-analysis was performed, estimating
the odds ratio of hip fracture in the treatment group with 95%
confidence intervals (CI) (Comprehensive Meta-Analysis software,
Biostat, Englewood, NJ, USA). Although the frequentist approach
to meta-analysis is much more common and popular in medical
research, one of its limitations is a lack of flexibility of modeling,
particularly relevant here when pooling data from cluster and
individually randomized trials. Between-study heterogeneity was
calculated on the log scale from posterior distribution of the
variance parameter of the Normal distribution of the log OR
estimates for Bayesian meta-analyses [22]. Between-study hetero-
geneity was assessed by calculation of the I
2 and Q-values for the
frequentist meta-analyses. For individually randomized trials
which could not be pooled, and for which no statistical analysis
was reported in the primary paper, we calculated the odds ratio of
hip fracture with 95% CI using an intention-to-treat approach
(CIA software, London, UK). The 25-hydroxy-vitamin D
measurements were converted from ng/ml to nmol/L by
multiplying by 2.496 [24]. Given the complexity of this scoping
review, in that multiple reviewers in multiple institutions, were
involved in multiple updates of multiple reviews, reviewer
agreement statistics were not formally calculated. More details
on the analyses are available from the corresponding author upon
request. Other details relating to the systematic review method-
ology are otherwise summarized in Checklist S1 (Prisma
Checklist).
Results and Discussion
Study Characteristics
The numbers of abstracts/citations and full-text papers
reviewed in each category of review are summarized in Table 1
(summary of trial flow). Within 6 respective searches (by category
of intervention), there was a total of 22,349 abstracts or citations
and 949 full-text papers reviewed in duplicate. Data from 20
randomized controlled trials were included in the final scoping
review, including: 7 trials on oral vitamin D (with or without
calcium) (total of 12,875 participants) [25;27–32, with supplemen-
tal information on reference 25 from reference 26], 2 trials on sun
exposure (as a form of vitamin D treatment) (total of 522
participants) [33;34], 1 trial on alendronate (n=327 participants)
[35], 1 trial on fluoride (including a total of 460 participants) [36],
4 trials on exercise/behavioral, or multimodal interventions (total
of 8,165 participants) [37–40], and 5 trials on hip protectors (total
of 2,594 participants) [41–45], of which four [41–44] were
previously summarized in a prior systematic review by our group
[22]) (Table 2). A recent hip protector trial by Kiel et al. (2007)
[46] was excluded from our review since participants who dropped
out or died were substituted with nonrandomized individuals,
violating an a priori exclusion criterion for this review [22;23].
Assessment of the Methodologic Quality of Included
Studies
A summary of the key features in the assessment of
methodologic quality of included studies is shown in Table 3.
Central computerized randomization was variably performed in
included trials. Placebo controls were used in most trials of oral
vitamin D (with the exception of the study by Law [29]), as well as
the trials of alendronate [35] and fluoride [36]. Placebo or sham
interventions were not used in any of the trials of exercise/
behavioral, or multi-faceted interventions. With the exception of
three trials of oral vitamin D (Chapuy 1994 [25], Chapuy 2002
[27], and Lyons 2007 [30]) in which compliance rates exceeded
80%, compliance was lower or not reported for the rest of the
intervention studies (Table 3). Compliance was lower than 80% in
all of the hip protector trials (Table 3). Fewer than half of studies in
this review reported losses to follow-up of less than 10% (excluding
deaths) and fewer than half reported the presence or absence of
adverse events (Table 3). Most cluster randomized studies reported
the unit of randomization [29;37–39;41;44;45] and adjusted the
treatment effect analysis for cluster randomization [29;37–39;44];
whereas the ICC was formally reported only in the multimodal
intervention trial by Cox et al. [38].
Vitamin D or Calcium
We included 7 randomized controlled trials on oral vitamin D,
including 3 trials utilizing vitamin D3 [25;27;31], and 4 trials
utilizing vitamin D2 [28–30;32]. In two vitamin D3 trials from
Chapuy et al [25;27], the control group received double placebo
instead of calcium and vitamin D, respectively. In the other
vitamin D studies, a specific placebo was not substituted for
calcium supplements (Table 3). However, none of the studies in
the long-term care setting was found to examine the independent
effect of calcium supplementation on hip fracture rates. In pooling
data from trials of oral vitamin D compared to placebo or usual
care (12,875 individuals) [25;27–32], the odds ratio (OR) for hip
fracture in the vitamin D-treated group was 0.86 (95% credibility
interval [CRI], 0.74, 0.98) (between-study heterogeneity on a log
scale, mean 1.40610
24, 95% CRI 1.40610
27, 6.77610
24)
(Table 2). The pooled odds ratios (with 95% CRI) for hip fracture
in the treatment group according to type and dose of vitamin D
are as follows: vitamin D3 (any dosage) - OR 0.78 (0.63, 0.93) (data
from 3 trials [25;27;31], n=4997), vitamin D3 at a dosage of $800
IU/day (with 1.2 g elemental calcium daily) – OR 0.71 (0.55,
0.87) (data from 2 trials [25;27], n=3853), vitamin D2 – OR 0.99
(0.79, 1.22) (data from 4 trials [28–30;32], n=7878). There was
only one trial in which a dosage of 400 IU daily of vitamin D3 was
utilized, and the relative risk of hip fracture in the treatment group
was reported to be 1.09 (95% confidence interval, 0.63, 1.63) [31].
Adverse events were very uncommon in the trials of oral vitamin
D, with the following incidence rates of hypercalcemia reported:
0.1% in the trial by Chapuy et al (1994) [25], 0.8% in the trial by
Chapuy et al (2002) [27], and 0.1% in the trial by Law et al. [29];
whereas there were no adverse events in the trial by Flicker et al.
[28]. The incidence of gastrointestinal side effects such as nausea,
diarrhea, or epigastric pain was similar between treatment and
control groups in the two trials by Chapuy et al. [25;27]. The
mean baseline 25-hydroxyvitamin D blood levels of participants
were reported to be #40 nmol/L in the following trials of oral
vitamin D: Chapuy 1994 [25], Chapuy 2002 [27], and Sato 2005
[32]. The mean baseline hydroxyl-vitamin D blood measurements
were .40 nmol/L in the studies by Lyons et al. [30] and Meyer et
al. [31] and in the control group studied by Law et al. [29]; these
data were not reported by Flicker et al. [28].
In a pooled analysis of intention-to-treat data from two trials in
which 15 minutes of daily sunlight exposure (on clear days) was
used as a form of vitamin D treatment [33;34], the odds ratio of
hip fracture in the treatment group was 0.43 (95% confidence
intervals, 0.10, 1.83, n=522) (between-study heterogeneity I
2
value of 34.5, Q-value 1.53 [1 degree of freedom], p=0.217) A
classical random effects meta-analysis was used since the Bayesian
random effects model could not achieve convergence using this
small dataset of small trials. No adverse events as a consequence of
sunlight exposure were reported by Sato et al. in one of these trials
[34]. The mean baseline 25-hydroxyvitamin D levels were
#40 nmol/L in the two trials testing sunlight exposure [33;34].
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Review
category
Author and
year (Ref)* Intervention
Study
population
(Sex)
Number
participants
randomized
(Institutions)
Follow-up
duration
(Months)
Number of Hip
Fractures in Treatment
(T) and Control (C)
groups (Percentage)
Pooled Odds Ratio
(OR) of Hip Fracture
in Intervention
Group Compared to
Controls { (Number
of participants
and trials)
Vitamin D
or calcium
Chapuy
1994 [25]
Vitamin D3 800
IU+1.2 g calcium
daily
All from nursing
homes
(All female)
3270 (180) 36 T: 138/1634 (8.4%)
C: 184/1636 (11.2%)
Oral vitamin D: Pooled
OR 0.86 (95%
credibility interval,
0.74, 0.98) (Pooled
n=12,875 in 7 trials)
Chapuy
2002 [27]
Vitamin D3 800
IU+1.2 g calcium
daily
All from nursing
homes
(All female)
583 (55) 24 T: 27/393 (6.9%)
C: 21/190 (11.1%)
Flicker
2005 [28]
Vitamin D2 10,000
IU/week or 1,000 IU
per day+0.6 g
calcium daily
Nursing home
and other
institutions
(Male and
female)
625 (149) 24 T: 3/313 (1.0%)
C: 7/312 (2.2%)
Law
2006 [29]
Vitamin D2 2.5 mg
every 3 months
(equivalent to
1,100 IU/day)
Nursing home
and other
institutions
(Male and
female)
3717 (118) 10 (Median
and mean)
T: 24/1762 (1.4%)
C: 20/1955 (1.0%)
Lyons
2007 [30]
Vitamin D2 2.5 mg
three times per
year (About 833
IU/day)
Nursing home
and other
institutions
(Male and female)
3440 (314) 36 T: 127/1725 (7.4%){
C: 126/1715 (7.3%){
Meyer
2002 [31]
Vitamin D3 400 IU
daily in 5 ml cod
liver oil
All from nursing
homes (Male
and female)
1144 (51) 24 T: 50/569 (8.8%)
C: 47/575 (8.2%)
Sato
2005 [32]
Vitamin D2 1,100
IU daily
Chronic geriatric
hospitalization
(Females, post-
stroke with
hemiplegia)
96 (1) 24 T: 0/48 (0%)
C: 4/48 (8.3%)
Sato 2005
(Sunlight) [33]
Outdoor sunlight
exposure in clear
weather for 15
minutes daily 1.2 g
calcium daily
Chronic geriatric
hospitalization,
Alzheimer’s
Disease (all
females)
264 (1) 12 T: 2/132 (1.5%)
C: 9/132 (6.8%)
Sunlight exposure:
Pooled OR 0.43 (95%
confidence interval
0.10, 1.83) (n=522 in 2
trials)l
Sato 2003
(Sunlight) [34]
Outdoor sunlight
exposure in clear
weather for 15
minutes daily
Chronic geriatric
hospitalization,
post-stroke
hemiplegia
(Males and
females)
258 (1) 12 T: 1/129 (0.8%)
C: 6/129 (4.7%)
Drug
therapies
Greenspan
2002 [35]
Alendronate 10mg
orally daily+Vitamin
D 400 IU daily (type not
specified) +Calcium
carbonate (OsCal
500, if dietary calcium
,1500 mg/day)
Nursing home
and other
institutions
(All female)
327 (25) 24 T: 2/163 (1.2%)Q
C: 4/164 (2.4%)Q
OR 0.50 (95%
confidence interval
0.09, 2.75) lQ (n=327
in 1 trial)
Alternative
medicines
Inkovaara
1975 [36]
Sodium monofluoro-
phosphate (25 mg
of fluorine
daily for first 5
months, then
25mg twice a week)
Municipal home
for the aged
(Males and
females)
460 (1) 8 T: 8/237 (3.4%)
C: 5/223 (2.2%)
(Femoral)
OR 1.52 (95%
confidence interval
0.49, 4.73) lQ (n=460
in 1 trial)
Exercise,
behavioral or
multimodal
Becker
2002 [37]
Multimodal
intervention: Staff
and resident
education, balance
and resistance
training, hip protectors
All in nursing
homes (Males
and females)
981 (6) 12 T: 17/509 (3.3%)
C: 15/472 (3.2%)
Relative Risk 1.11 (95%
confidence interval
0.49, 2.51) lh (Adjusted
for cluster
randomization)
(n=981 in 1 trial)
Nursing Home Hip Fractures
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Greenspan et al examined the use of oral alendronate 10 mg daily
compared to placebo in one randomized controlled trial including 327
institutionalized elderly in 25 institutions [35]. In this study, which was
not powered to detect differences in fracture outcomes, the OR of hip
fracture in the treatment group was calculated to be 0.50 (95% CI 0.09,
2.75). Adverse events were not significantly increased in the
alendronate-treated group compared to the controls in this study [35].
In one trial comparing oral fluoride to placebo [36], hip
fractures were not significantly reduced in the treatment group
(OR 1.52, 95% CI 0.49, 4.73). Moreover, this study was
terminated early due to excessive rates of abdominal discomfort,
weight loss, hospitalization, and spontaneous fractures experienced
in the fluoride group [36].
Exercise, Behavioral, or Multimodal Interventions
One exercise study [40] and 3 trials of multimodal interventions
[37–39] were included in this review (Table 2). In the one study
comprised of strictly an exercise intervention, Sakamoto et al.
asked participants in the intervention arm, to stand on their right
leg for one minute and then their left leg for another minute, for a
total of 2 minutes, three times a day (with eyes open); a control
group was observed without any exercise intervention in the same
time period [40]. In the study by Sakamoto et al, the unipedal
standing exercise program was reported to reduce falls (although
one treatment group participant who fell frequently was excluded
from the analysis, not intention-to-treat analysis) (p,0.001);
however the risk of hip fracture was not significantly reduced
over six months (n=553 participants randomized) [40]. Becker
Review
category
Author and
year (Ref)* Intervention
Study
population
(Sex)
Number
participants
randomized
(Institutions)
Follow-up
duration
(Months)
Number of Hip
Fractures in Treatment
(T) and Control (C)
groups (Percentage)
Pooled Odds Ratio
(OR) of Hip Fracture
in Intervention
Group Compared to
Controls { (Number
of participants
and trials)
Cox
2003 [38]
Multimodal
intervention including
staff education and
individual risk
assessment with
feedback and
advice to physicians
Nursing home
and other
institutions
(Male and female)
6229 (58 PCO
clusters)
12 T: Not reported/3476
C: Not reported/2753
Relative Risk 0.86 (95%
confidence interval
0.63, 1.18) lh£
(Adjusted for cluster
randomization)
(n=5637 residents in 1
trial)
Jensen
2002 [39]
Multimodal
intervention: Staff
education,
environmental
modification, exercise
program, drug
modification (for falls
prevention), select
specialist referral, hip
protectors
All in nursing
homes (Males
and females)
402 (9) 11 week
intervention
with 34 week
follow-up
T: 3/194 (1.5%)
C: 12/208 (5.8%)
Unadjusted OR 0.25
(95% confidence
interval 0.05, 1.13)£ lh
OR Adjusted for
Baseline Variables 0.23
(95% confidence
interval 0.06, 0.94)£ hm
(All adjusted for cluster
randomization)
(n=384 in 1 trial)
Sakamoto
2006 [40]
Exercise: Daily
supervised uni-pedal
standing balance
exercise
Nursing home and
other institutions
(Male and female)
553 (32) 6 T: 1/337 (3.0%)
C: 1/216 (4.6%)
Not significant
(p.0.999) lh£ (n=527
in 1 trial)
Hip
protectors
Sawka 2007
(Systematic
review, data
from 4 trials) [22]
(Ekman 1997,
Harada 2001,
Jantti 1998,
Meyer 2003)
Hip protectors
(Shields on
both hips)
All nursing home
residents
(Harada - all
female, others -
male and female)
1,922
(Ekman – 4,
Harada – 6,
Jantti - 1,
Meyer 42)
Range 11–15 Ekman: T: 4/302 (1.3%)
C: 17/442 (3.8%) Harada:
T: 1/88 (1.1%) C: 8/76
(10.5%) Jantti: T: 1/36
(2.8%) C: 7/36 (19.4%)
Meyer: T: 21/459 (4.6%)
C: 42/483 (8.1%)
Hip Protectors Pooled
OR 0.40 (95%
credibility interval 0.27,
0.56) (Pooled n=2,594
individuals in 5 trials)
Koike
2009 [45]
Hip protectors
(shields on both
hips) and leaflet on
fracture prevention
All nursing home
residents (or
equivalent){ (All
female)
672 12–26s T: 9/345 (5.5%)
C: 39/327 (11.9%)
*Ref is the reference number listed at the end of this paper.
{Intention to treat analysis unless otherwise indicated.
{The primary author confirmed through e-mail correspondence that all residents had onsite 24-hour per day nursing care available.
sTime from allocation to treatment to end of follow-up period (allocation in January, 2004 and March, 2005 to end of follow-up in March, 2006).
l A Bayesian random effects meta-analysis could not be performed for this data.
QCalculated.
hResults reported in the primary paper.
£The treatment effect reported by the primary author is not an intention to treat analysis as the number randomized is higher than the number for which the statistical
test was performed.
mThe baseline variables adjusted for in this model included: Mini-Mental Status Examination score, Barthel index score, physical restraints and delirium, sex and history
of falls, and age.
doi:10.1371/journal.pone.0009515.t002
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Review
category
First author
and year
(Ref)*
Level of
randomization
Central
computerized
randomization
Use of placebo or
sham in control
group
Losses to
follow-up
,10% (Excluding
deaths)
Compliance
with treatment
intervention
.80%
Reported
adverse events
Vitamin D
or calcium
Chapuy
1994{ [25]
Individual Not reported Double placebo (for
vitamin D and calcium)
Yes Yes at 18
months
Yes
Chapuy
2002 [27]
Individual Not reported Double placebo (for
vitamin D and
calcium)
No Yes Yes
Flicker
2005 [28]
Individual Yes Placebo (weekly or
daily) +0.6 g
calcium daily
No No Yes (No adverse
events occurred)
Law
2006 [29]
Cluster (30-bedded
residential unit or
small facility
without units)
Yes No (Usual care) Yes Not reported
(2% stopped
treatment)
Yes
Lyons
2007 [30]
Individual Yes Placebo Yes Yes No
Meyer
2002 [31]
Individual No (Allocated
by day of birth)
Placebo No Unclear
(2% stopped
treatment)
No
Sato
2005 [32]
Individual Yes Placebo Unclear Not reported No
Sato 2005
(Sunlight) [33]
Individual Yes No (Usual care+1.2g
elemental calcium
daily)
Yes Not reported No
Sato 2003
(Sunlight) [34]
Individual Yes No (Usual care) No Not reported Yes (No adverse
events occurred)
Drug
therapies
Greenspan
2002 [35]
Individual Yes Placebo+Vitamin D
400 IU daily (type not
specified) +Calcium
carbonate (OsCal 500,
if dietary calcium
,1500 mg/day)
Not reported Not reported Yes
Alternative
medicines
Inkovaara
1975 [36]
Individual No (Allocated by
year of birth – odd
or even number)
Matched placebo
(30 mg sodium
bicarbonate)
No Not reported Yes
Exercise,
behavioral
or multimodal
Becker
2002 [37]
Cluster (Nursing
home)
No (Allocated by
sealed envelopes)
No (Usual care) Yes No No
Cox
2003 [38]
Cluster (Primary
Care Organizations
[PCO] representing
multiple nursing
homes)
Yes No (Usual care) Yes for individuals Not clearly
reported
No
Jensen
2002 [39]
Cluster (Nursing
home)
No (Allocated by
sealed envelopes)
No (Usual care) No Not clearly
reported for all
components of
intervention
No
Sakamoto
2006 [40]
Individual No (Allocated by
random number
table)
No (Usual care) Yes Not clearly
reported
No
Hip
protectors
Sawka 2007
(Systematic
review, data
from 4
trials){ [22]
Jantti – Individual
Others - Cluster
(Ekman 1997, Harada
2001, Jantti 1998,
Meyer 2003) Yes -
Meyer study, not
others
No (Usual care) No No (Unclear for
Meyer 2003l)
No
Koike
2009 [45]
Cluster No (Random
number table)
No (Usual care
and a leaflet on
fracture prevention)
Yes No (79.7%) Yes
*Ref is the reference number listed at the end of this paper.
{Some data reported in a prior paper by Chapuy et al. in 1992 on the same study population [reference 26].
{Some data reported in a prior paper by Sawka et al. in 2005 [reference 23] or the primary references.
lIn the hip protector study by Meyer et al. [reference 44], the primary author relayed through e-mail correspondence that hip protector compliance was not measured,
but a ‘‘worst-case’’ estimate of 34% for hip protector use in the treatment group was reported.
doi:10.1371/journal.pone.0009515.t003
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combination of the following components over 12 months (with
choice of resident-specific interventions dependent on resident
preference): a) staff training in a 60-minute course with written
information on falls, b) written information on fall prevention for
all residents, with a personal consultation on fall prevention
offered by a nurse or exercise instructor to all residents who were
not chair- or bed-bound, c) an environmental hazard check of the
facility with discussion of the results with staff and administrators,
d) balance exercises and progressive resistance training with ankle
weights and dumbbells (20 minutes of balance exercise in a
standing position and walking if possible with nine different
standardized progressive resistance training exercises for a
maximum of 10 repetitions of resistance exercises in two sets,
including all major muscle groups), and e) hip protectors offered to
residents who could stand (assisted or unassisted) or who could rise
from a chair unattended (5 pairs of either Safety Pants, Raunomo
Oy, Tampere, Finland or Safehip, Tytex, Ikast, Denmark) [37].
Although falls were significantly reduced in the study by Becker et
al (relative risk [RR] 0.55, 95% confidence interval [CI] 0.41,
0.73), hip fractures were not significantly reduced (RR 1.11, 95%
CI 0.49, 2.51) (n=981 participants randomized) [37]. In another
study of a multi-modal general and resident-specific intervention,
Jensen et al studied the following strategy: a) a 4-hour educational
session on falls for staff, b) environmental modification by staff and
study physiotherapists (including removal of loose carpets,
provision of grip bars, new beds, new firm mattresses, furniture
changes, and improved lighting), c) supervised resident-specific
exercise training to improve physical function, focusing on
strength, balance, gait, and safe transfer, d) supply and repair of
mobility-related aids by physiotherapists, e) medication adjust-
ments intended to reduce fall risk, f) provision of hip protectors to
residents who were considered particularly prone to sustaining a
fall-related hip fracture, g) post-fall problem-solving conferences,
and h) staff guidance by researchers with ongoing discussions
about safety issue of fall-prone residents [39]. In the study by
Jensen et al, all residents were screened for their risk of falling
(interviewed and assessed by physiotherapists at baseline);
individuals in the control arm received usual care [39]. Jensen et
al reported a significantly reduced risk of falls in the treatment
group compared to controls (risk ratio 0.78, 95% CI 0.64, 0.96)
and that the risk of hip fracture was significantly reduced in a
secondary analysis adjusting for baseline variables (relative risk
0.23, 95% CI 0.06, 0.94, n=384, not intention-to-treat analysis).
In a third trial, Cox et al. studied the following multimodal
intervention over 12 months: a) a half-day central training session
with written materials for staff focusing on bone health and
osteoporosis, falls and fall prevention, risk factors for falls and
fractures, and risk assessment tools for fracture (the Black fracture
risk assessment tool and the STRATIFY fall risk assessment tool),
b) care home staff assessing individual risk of fracture and falls
using the Black and STRATIFY tools with results sent to specialist
osteoporosis nurses, and c) individual assessment results and
treatment recommendations sent from specialized osteoporosis
nurses to treating physicians [38]. In the study by Cox et al., falls,
total fractures, or hip fractures were not significantly reduced by
the educational and risk assessment/recommendation strategy,
even though rates of prescription of bisphosphonates and calcium/
vitamin D rose (n=6229 participants randomized) [38].
Hip Protectors
As part of this review, we updated a prior systematic review
from our group [22]. Our original review included data from 4
trials, including those from Ekman 1997 [41], Harada 2001 [42],
Jantti 1998 [43], Meyer 2003 [44]. In this update, an additional
study was included from Koike et al. 2009 [45]. All of these trials
tested 2-sided hard shell hip protectors, and the Safehip brand was
used by Harada [42], Meyer (2003), and Koike (2009) [45]. In the
newest study by Koike et al., female residents were eligible to
participate in the trial if they were aged $65 years and had at least
one of the following risk factors for fracture: history of prior
fracture, low body-mass index, family or individual history of hip
fracture, frequent faller status, current smoker, or other frail
residents [45]. Four of the hip protector trials [41;42;44;45]
included in this review were cluster randomized, with the unit of
randomization being the entire LTC facility in three trials
[41;44;45] or a room (usually containing 4 beds) in one study
[42]. The incidence of hip fracture in the control groups of
included studies ranged from 3.8% to 19.4% over the course of the
studies (range of respective trial durations 11 to 26 months) ([41–
45], Table 2). In pooling data from the 5 hip protector trials, the
odds ratio of hip fracture in the treatment group was 0.40 (95%
credibility interval 0.27, 0.56) (n=2,594 individuals, Table 1)
(between-study heterogeneity on a log scale, mean 1.70610
24,
95% CRI 2.01610
27, 8.60610
24). The adherence rate for the hip
protector trials was as follows: 44% at 11 months in the study by
Ekman [41], 70% at 12 months in the study by Harada [42], 68%
at 12 months in the study by Jantti [43], 79.7% throughout the
study period (up to 26 months) in the study by Koike et al. 2009
[45], and 34% (‘‘worst case estimate’’) in the study by Meyer [44].
It is important to acknowledge the findings of a recent trial by
Kiel et al. (2007), in which institutions were cluster randomized to
either a right or left-sided hip protector as this study reported
findings that are contradictory to our pooled analysis [46]. The
study by Kiel et al. was excluded from our review since
participants who dropped out or died were substituted with
nonrandomized participants, violating an a priori exclusion
criterion established in our prior review on this topic (and
potentially resulting in bias, if participants from one group were
preferentially replaced) [22;23]. However, in the study by Kiel
et al. [46], the incidence of hip fracture on the protected side
(3.1%, 95% CI 1.8, 4.4%) was not significantly different compared
to the unprotected side (2.5%, 95% CI 1.3, 3.7%) (p=0.70)
(n=1042 protected and 1042 unprotected hips followed for 20
months). This study was terminated early because of futility [46].
Summary and Discussion
In summary, we have reviewed data from randomized
controlled trials of interventions for the reduction of risk of hip
fracture in elderly LTC facility residents. Using a Bayesian meta-
analysis, we found evidence that supplementation with Vitamin D,
particularly Vitamin D3 $800 IU daily, reduces the risk of hip
fracture in elderly nursing home residents. These results are in
keeping with prior results of meta-analyses by Bischoff-Ferrari et
al., particularly for doses of vitamin D3 exceeding 400 IU per day,
where data were pooled from institutionalized and community
populations using a non-Bayesian analytic technique [24;47].
Neither sunlight exposure nor fluoride treatment was found to
significantly reduce hip fractures. In one trial examining the use of
oral alendronate in institutionalized elderly, hip fractures were not
significantly reduced; however the trial was not adequately
powered to detect fracture outcome differences (n=327) [35]. It
is relevant to note that in a recent Cochrane systematic review and
meta-analysis, alendronate was shown to reduce the risk of hip
fracture in high risk secondary prevention populations [48], upon
pooling data on institutionalized elderly [35] with community
populations. Thus, it could be extrapolated that potent amino-
bisphoshonates such as alendronate may reduce hip fracture when
Nursing Home Hip Fractures
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not have prescribing contra-indications and who are able to
tolerate the drug upon proper administration. In the alendronate
trial performed in a LTC population, adverse events were not
suffered to a greater extent in the treatment group compared to
controls [35], albeit relatively small sample size may have been a
limiting factor in detecting this outcome. In a trial of a unipedal
standing exercise program, Sakamoto et al. reported a reduced risk
of falls in the LTC setting but no significant effect on hip fractures
[40]. Falls were also reduced in two studies of multimodal
interventions [37;39], with one study of a multi-modal intervention
by Jensen et al. suggesting a reduction in hip fractures in one of
several secondary analyses [39]. Some important differences
between the multimodal intervention offered by Jensen et al.
[39], in which hip fractures were reduced, compared to the
intervention offered Becker et al. [37], in which hip fractures were
not reduced, included: more intensive staff training, more ongoing
support on falls prevention, supply and repair of mobility aids, and
medication adjustments, in the former study [39]. Of note, in a
study by Cox et al, a staff education and risk assessment strategy
did not significantly reduce falls or hip fractures in LTC facilities
[40]. One of the main differences between the program offered by
Cox et al. [38] compared to the interventions provided by Becker
et al. [37] and Jensen et al. [39] is the performance of
environmental hazard checks in facilities as well as direct offering
of exercise programs or hip protectors to residents in the latter
studies. In this review, we also found some evidence that hip
protectors may reduce the risk of hip fracture in institutionalized
elderly in a pooled analysis of 2-sided devices. However, a recent
large trial of 1-sided hip protectors was negative [46], igniting
some controversy about this intervention. As acknowledged by the
authors of this study, ‘‘the use of a single pad is not analogous to
pad use in the real world and may have caused unanticipated
changes in behavior’’ [49]. Continued debate and uncertainty
about the efficacy of hip protectors is expected, given the
heterogeneity of findings between studies of 2-sided and 1-sided
devices. However, given that 2-sided devices are the norm used in
clinical practice, and that pooled analyses or randomized
controlled trials of this intervention have shown reduction of hip
fractures, it may not be appropriate to discount the potential
benefit of this intervention in the LTC setting.
This scoping review is subject to several limitations, including a
relative paucity of large trials such as those of pharmacologic
therapies, the relatively small size of some of the included studies, the
imputation of intra-cluster correlation coefficients for pooled cluster
randomized studies not reporting this value, the inherent methodo-
logic limitations of many of the primary studies (such as poor
reporting of compliance rates, a lack of placebo or sham interventions
for trials of some interventions, and the lack of reporting of intention-
to-treat analyses for some studies), the possibility of reporting bias,
and the potential for publication bias (as only published studies were
included). We did not specifically assess reporting or publication bias
in this review, given the relatively small number of studies included in
each category. The strengths of this review include the relatively
broad scope of interventions examined, the use of systematic search
strategies, duplicate reviews and duplicate abstraction of data, and the
use of a Bayesian meta-analysis model designed for pooling of data
from individually and cluster-randomized trials, and the examination
of a clinically important outcome.
In conclusion, we would recommend routine supplementation
with Vitamin D3 $800 IU daily for elderly nursing home
residents, in considering the potential benefit in reduction of hip
fractures, general ease of administration, and low incidence of side
effects of this intervention. Multimodal strategies, including staff
and resident education on falls and fractures, environmental
modification, exercise training, and offering of hip protectors, as
those described in the trial by Jensen et al. [39] appear to be
beneficial in reducing falls, which is a desirable outcome in itself
and may warrant implementation, if feasible and affordable for a
facility. However, larger studies are required to confirm whether
such multimodal interventions reduce hip fractures in LTC.
Decision making about pharmacologic treatment with potent
bisphosphonates or application of hip protectors is complex, given
that the former has not been proven to reduce the risk of hip
fractures in the nursing home setting (with evidence of efficacy of
hip fracture prevention largely founded in larger community-
based studies], and some conflicting findings in the medical
literature for the latter intervention. In considering the limitations
of the best available evidence, it may be reasonable to reserve
pharmacologic therapy or hip protectors for nursing home
residents at highest risk of hip fracture, such as residents with
prior fragility fracture or multiple risk factors (especially if any
vitamin D insufficiency or deficiency has first been treated].
Careful consideration must be given to any contraindications to
bisphosphonate therapy or the feasibility of establishing compli-
ance with hip protectors, if their use is contemplated in the nursing
home setting. Clearly, more research on effective strategies to
reduce hip fractures in LTC is needed, including more studies on
pharmacologic treatments, exercise, behavioural, or multi-modal
strategies, and hip protectors.
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